Point State Capital LP Altimmune, Inc. Transaction History

Point State Capital LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$5.9 - $9.45 $796,500 - $1.28 Million	-135,000 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$8.69 - $12.48 $651,750 - $936,000	75,000 Added 125.0%	135,000 $1.24 Million
Q3 2021 Nov 15, 2021	SELL	$8.43 - $16.81 $337,200 - $672,400	-40,000 Reduced 40.0%	60,000 $679,000
Q2 2021 Aug 13, 2021	BUY	$9.85 - $16.46 $985,000 - $1.65 Million	100,000 New	100,000 $985,000
Q1 2021 May 14, 2021	SELL	$12.71 - $24.31 $635,500 - $1.22 Million	-50,000 Closed	0 $0

Q4 2020 Feb 16, 2021	BUY	$7.84 - $14.22 $392,000 - $711,000	50,000 New	50,000 $564,000

185

44.4M

1.1M

647K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $325M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

Stay updated on Point State Capital LP with notifications on news.